tiprankstipranks

Cullinan Therapeutics assumed with an Overweight at Morgan Stanley

Morgan Stanley assumed coverage of Cullinan Therapeutics (CGEM) with an Overweight rating and a price target of $35, down from $38. The firm sees upside potential for CLN-978 with the upcoming initial clinical data and is positive on the pipeline, focusing on the near-term zipalertinib presentation and CLN-619 data, the analyst tells investors.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue